Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to -$556,000.

  • Catalyst Pharmaceuticals' Cash from Investing Activities fell 160.00% to -$26,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$383,000, marking a year-over-year increase of 99.71%. This contributed to the annual value of -$556,000 for FY2024, which is 99.81% up from last year.
  • As of FY2024, Catalyst Pharmaceuticals' Cash from Investing Activities stood at -$556,000, which was up 99.81% from -$293.5 million recorded in FY2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Cash from Investing Activities peaked at $9.2 million during FY2022, and registered a low of -$293.5 million during FY2023.
  • For the 3-year period, Catalyst Pharmaceuticals' Cash from Investing Activities averaged around -$94.9 million, with its median value being -$556,000 (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 183.56% in 2022, then slumped by 3,287.12% in 2023.
  • Yearly analysis of 5 years shows Catalyst Pharmaceuticals' Cash from Investing Activities stood at -$5.0 million in 2020, then tumbled by 119.94% to -$11.0 million in 2021, then spiked by 183.56% to $9.2 million in 2022, then crashed by 3,287.12% to -$293.5 million in 2023, then surged by 99.81% to -$556,000 in 2024.